An apparatus for the production of solid dosage forms is presented, wherein the apparatus comprises a material processing chamber which is operable for manufacturing a product according to a pre-set product formation process path. The apparatus has at least one sensor for continuously monitoring formation of the product in the material processing chamber during the product formation process non-invasively in real time by sensing at least one product functional attribute value and a means for comparing each sensed product functional attribute value with a desirable product functional attribute value for that point on the product formation process path. A controller controls operation of the material processing chamber in response to the sensed product functional attribute value for maintaining the product on the product formation process path.

An apparatus for the production of solid dosage forms is presented, wherein the apparatus comprises a material processing chamber which is operable for manufacturing a product according to a pre-set product formation process path. The apparatus has at least one sensor for continuously monitoring formation of the product in the material processing chamber during the product formation process non-invasively in real time by sensing at least one product functional attribute value and a means for comparing each sensed product functional attribute value with a desirable product functional attribute value for that point on the product formation process path. A controller controls operation of the material processing chamber in response to the sensed product functional attribute value for maintaining the product on the product formation process path.

An apparatus for liquefying solid pills includes a grinder configured to grind the solid pills to a powder, a receptacle configured to attach to the grinder and to capture the powder, and a cap configured to attach to the receptacle. The cap includes a port therethrough in fluid connection with the receptacle. The port is configured to mate with a tip of a syringe.

An apparatus for liquefying solid pills includes a grinder configured to grind the solid pills to a powder, a receptacle configured to attach to the grinder and to capture the powder, and a cap configured to attach to the receptacle. The cap includes a port therethrough in fluid connection with the receptacle. The port is configured to mate with a tip of a syringe.

A resveratrol composition and its preparation method and application are disclosed, which relates to the technical field of resveratrol solid dispersion preparation. A resveratrol composition is prepared from following raw materials: 6%-60% by weight of resveratrol, and 40%-94% by weight of poloxamer. The disclosure mixes the resveratrol and poloxamer in proportion to prepare a composition, and further improves the dissolution and bioavailability of the resveratrol in combination with microencapsulation technology. The preparation process is suitable for industrialization and has good application and promotion prospects.

A resveratrol composition and its preparation method and application are disclosed, which relates to the technical field of resveratrol solid dispersion preparation. A resveratrol composition is prepared from following raw materials: 6%-60% by weight of resveratrol, and 40%-94% by weight of poloxamer. The disclosure mixes the resveratrol and poloxamer in proportion to prepare a composition, and further improves the dissolution and bioavailability of the resveratrol in combination with microencapsulation technology. The preparation process is suitable for industrialization and has good application and promotion prospects.

Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

A system for continuous processing of powder products includes a first inlet configured to input a first dry powder product, a second inlet configured to input a second dry powder product, and a dry powder mixing device that mixes the first dry powder product together with the second dry powder product to form a product mixture. An outlet dispenses the product mixture from the dry powder mixing device. A production machine is included and has a powder feed frame comprising a feed frame inlet connected to the outlet of the dry powder mixing device. The outlet of the dry powder mixing device is positioned at a lower level than the feed frame inlet. A product conveying device is connected between the outlet of the dry powder mixing device and the feed frame inlet to continuously convey the product mixture from the dry powder mixing device to the feed frame inlet.

A process and to an apparatus for production of a granular cannabinoid material essentially soluble in aqueous medium, wherein a matrix liquid composed of a first liquid that dissolves a cannabinoid or composed of a first liquid that dissolves a cannabinoid and a second liquid that forms an emulsion with the first liquid and a cannabinoid dissolved in the first liquid or emulsion is produced. The matrix liquid is dried by convection, and wherein the apparatus has a vessel system having an inlet and a matrix liquid outlet for production of the matrix liquid and a drying apparatus fluidically connected to the matrix liquid outlet of the vessel system.